Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps-Reference-Cited by-同舟云学术

Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps

Published:2023-09-04 Issue:1 Volume:34 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

van der Rijst Lisa P.¹²,van Royen-Kerkhof Annet³,Pasmans Suzanne G. M. A.⁴⁵,Schappin Renske⁴⁵,de Bruin-Weller Marjolein S.²,de Graaf Marlies¹²^ORCID

Affiliation:

1. Department of Dermatology and Allergology, University Medical Center Utrecht, Wilhelmina Children’s Hospital, Utrecht, the Netherlands

2. Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands

3. Department of Pediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, the Netherlands

4. Department of Dermatology, Centre of Pediatric Dermatology, Erasmus MC University Medical Centre Rotterdam-Sophia Children’s Hospital, Rotterdam, the Netherlands

5. Department of Dermatology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2023.2254567

Reference36 articles.

1. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

2. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

3. Clinicaltrials.gov. Efficacy and safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. NCT03985943 [accessed 2023 Feb 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT03985943

4. Clinicaltrials.gov. Evaluation of the efficacy and safety of lebrikizumab (LY3650150) in moderate to severe atopic dermatitis (ADvocate2). NCT04178967 [accessed 2023 Feb 14]. [Available from: https://clinicaltrials.gov/ct2/show/NCT04178967

5. Sanofi. Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis. Paris and Tarrytown (NY): Sanofi; 2023; [accessed 2023 Apr 3]. Available from: www.sanofi.com/en/media-room/press-releases/2023/2023-03-21-06-00-00-2630956

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis;Pediatric Allergy and Immunology;2024-06